全球犬异位性皮肤炎药物市场按药物类别、给药途径、剂型、分销管道和地区划分

2025 年全球犬异位性皮肤炎治疗市场规模估计为 16.485 亿美元，预计到 2032 年将达到 32.763 亿美元，2025 年至 2032 年的复合年增长率为 10.3%。

图。犬异位性皮肤炎治疗市场占有率（%），按地区，2025 年

犬异位性皮肤炎是宠物狗的慢性皮肤病。其特征是皮肤发炎和感染。在过去的几十年里，宠物狗中异位性皮肤炎的盛行率增加。其确切病因尚不清楚，但据认为与遗传、环境因素以及免疫系统对通常无害的物质的过度反应有关。患有异位性皮肤炎的狗狗会出现严重的搔痒、发炎和皮肤病变，让它们非常不舒服。传统上，人们使用抗组织胺和皮质类固醇来控制症状。然而，这些药物不能治癒疾病，长期使用可能会引起副作用。因此，需要安全有效的治疗方法来缓解症状并改善病情。一些製药公司正在投资研发生物目标、免疫调节剂和其他新型治疗方法。

市场动态：

全球犬异位性皮肤炎药物市场受到宠物主人数量增加、研发活动活性化、犬异位性皮肤炎盛行率上升以及新产品推出等因素的推动。近年来，该市场核准并推出多种新药，扩大了治疗选择。然而，新药的高昂治疗费用是一个障碍。市场参与企业将看到尚未开发的新兴市场的成长机会和先进治疗方法的进一步机会。

本研究的主要特点

• 本报告对全球犬异位性皮肤炎治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球犬异位性皮肤炎治疗药物市场的主要企业简介是根据公司亮点、产品系列、关键亮点、业绩和策略等参数列出的。
• 本报告的见解可以帮助负责人和企业经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球犬异位性皮肤炎治疗药物市场迎合了该行业的各种相关人员，例如投资者、供应商、产品製造商、分销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球犬异位性皮肤炎治疗市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 最新动态
• 品牌与价格分析
• 监管情景
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球犬异位性皮肤炎治疗市场：COVID-19 疫情的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 全球犬异位性皮肤炎治疗市场依药物类别划分（2020-2032 年）

• Janus激酶抑制剂
• 抗组织胺药
• 单株抗体
• 抗生素
• 过敏免疫治疗/脱敏治疗
• 其他的

6. 全球犬异位性皮肤炎治疗市场依给药途径划分（2020-2032 年）

• 注射
• 口服
• 局部的

第 7 章 全球犬异位性皮肤炎治疗市场按剂型划分（2020-2032 年）

• 锭剂
• 奶油
• 喷
• 其他的

8. 全球犬异位性皮肤炎治疗市场依通路划分（2020-2032 年）

• 在线的
• 离线

第 9 章 全球犬异位性皮肤炎治疗市场按地区划分（2020-2032 年）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• 公司简介
  • Bioiberica SAU
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

第 11 章 分析师观点

• 命运之轮
• 分析师观点
• Coherent Opportunity Map（COM）

第 12 章参考文献与调查方法

• 参考
• 调查方法

Global Canine Atopic Dermatitis Treatment Drugs Market is estimated to be valued at USD 1,648.5 Mn in 2025 and is expected to reach USD 3,276.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.3% from 2025 to 2032.

Figure. Canine Atopic Dermatitis Treatment Drugs Market Share (%), By Region 2025

Canine atopic dermatitis is a chronic skin condition observed in domestic dogs. It is characterized by inflammation and infections of the skin. The prevalence of atopic dermatitis has been increasing among pet dogs over the past few decades. The exact causes are unknown, but it is believed to involve genetic and environmental factors that cause the immune system to overreact to substances that are normally harmless. Dogs with atopic dermatitis experience severe itching, inflammation, and skin lesions that lead to discomfort. Antihistamines and corticosteroids have traditionally been used to manage the symptoms. However, they do not cure the condition and long-term use can cause side effects. Therefore, there is a need for safe and effective treatment drugs that can relieve symptoms and modify the disease. Several pharmaceutical companies are investing in research and developing targeted biologics, immunomodulators, and other novel treatment approaches.

Market Dynamics:

The global canine atopic dermatitis treatment drugs market is driven by factors such as rising pet ownership, rising research and development activities, and increasing prevalence of canine atopic dermatitis, and new product launches. The market has witnessed the approval and launch of several new drugs in recent years which has expanded the treatment options available. However, high treatment costs associated with novel drugs is a restraint. The market players have opportunities for growth in untapped emerging markets and further development of advanced therapeutics.

Key Features of the Study:

• This report provides an in-depth analysis of the global canine atopic dermatitis treatment drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global canine atopic dermatitis treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bioiberica S.A.U, Dechra Pharmaceuticals PLC, Elanco, NIPPON ZENYAKU KOGYO CO., LTD, Vimian, TORAY INDUSTRIES, INC., Zoetis, Virbac, Ceva, Bimeda, Inc., Vivaldis, VetriMax Veterinary Products, Vetoquinol, and Royal Canin North America.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global canine atopic dermatitis treatment drugs market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global canine atopic dermatitis treatment drugs market.

Detailed Segmentation-

• Drug Class:
  • Janus Kinase Inhibitors
  • Antihistamines
  • Monoclonal Antibodies
  • Antibiotics
  • Allergic Immunotherapy/Desensitization Therapy
  • Others
• Route of Administration:
  • Injectable
  • Oral
  • Topical
• Dosage Form:
  • Tablets
  • Creams
  • Spray
  • Others
• Distribution Channel:
  • Online
  • Offline
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Bioiberica S.A.U
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Brand and Pricing Analysis
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Canine Atopic Dermatitis Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 impact on the market

5. Global Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Janus Kinase Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Antihistamines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Monoclonal Antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Allergic Immunotherapy/Desensitization Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Canine Atopic Dermatitis Treatment Drugs Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Topical
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Canine Atopic Dermatitis Treatment Drugs Market, By Dosage Form, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Tablets
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Creams
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Spray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Canine Atopic Dermatitis Treatment Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Online
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Offline
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Canine Atopic Dermatitis Treatment Drugs Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Bioiberica S.A.U
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

11. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact